{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:38:10Z","timestamp":1767843490784,"version":"3.49.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["HMRF 06171706"],"award-info":[{"award-number":["HMRF 06171706"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cpet.2023.12.007","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:58:16Z","timestamp":1704340696000},"page":"207-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["PET\/Computed Tomography Transformation of Oncology"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-5297","authenticated-orcid":false,"given":"Elaine Yuen Phin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-9838","authenticated-orcid":false,"given":"Pun Ching","family":"Philip Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8330-0970","authenticated-orcid":false,"given":"Ka Yu","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuk Tak","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4602-2324","authenticated-orcid":false,"given":"Wan Kam","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib1","first-page":"1369","article-title":"A\u00a0combined PET\/CT scanner for clinical oncology","volume":"41","author":"Beyer","year":"2000","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.007_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2967\/jnumed.120.257725","article-title":"20 Years of PET\/CT: a conversation with david Townsend and thomas beyer","volume":"61","author":"Townsend","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/gyno.1993.1272","article-title":"Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG)","volume":"51","author":"Hubner","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1006\/gyno.2000.5768","article-title":"Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography","volume":"77","author":"Grab","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1148\/radiol.2233001850","article-title":"Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings","volume":"223","author":"Fenchel","year":"2002","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MNM.0b013e3281afa256","article-title":"Diagnostic accuracy of 18F-FDG PET\/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology","volume":"28","author":"Castellucci","year":"2007","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.11.022","article-title":"The diagnostic value of PET\/CT for primary ovarian cancer--a prospective study","volume":"105","author":"Risum","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13139-013-0197-5","article-title":"Differential diagnosis of borderline ovarian tumors from stage i malignant ovarian tumors using FDG PET\/CT","volume":"47","author":"Kim","year":"2013","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MNM.0b013e328345b339","article-title":"FDG-PET\/CT for diagnosis of primary ovarian cancer","volume":"32","author":"Kitajima","year":"2011","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/IGC.0000000000000074","article-title":"Diagnostic value of preoperative SUVmax on FDG-PET\/CT for the detection of ovarian cancer","volume":"24","author":"Tanizaki","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1148\/radiol.2019191150","article-title":"O-RADS US risk stratification and management system: a consensus guideline from the ACR ovarian-adnexal reporting and data system committee","volume":"294","author":"Andreotti","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib12","doi-asserted-by":"crossref","first-page":"e1919896","DOI":"10.1001\/jamanetworkopen.2019.19896","article-title":"Ovarian-adnexal reporting data system magnetic resonance imaging (O-RADS MRI) score for risk stratification of sonographically indeterminate adnexal masses","volume":"3","author":"Thomassin-Naggara","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib13","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpet.2023.12.007_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2214\/ajr.182.1.1820227","article-title":"Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer","volume":"182","author":"Yoshida","year":"2004","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.007_bib16","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00259-008-0890-2","article-title":"Diagnostic accuracy of integrated FDG-PET\/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT","volume":"35","author":"Kitajima","year":"2008","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.10.059","article-title":"Diagnosis and staging of primary ovarian cancer: correlation between PET\/CT, Doppler US, and CT or MRI","volume":"116","author":"Nam","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib18","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","article-title":"FDG-PET\/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy","volume":"80","author":"De Iaco","year":"2011","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2013.08.023","article-title":"A\u00a0prospective comparison of integrated FDG-PET\/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer","volume":"131","author":"Hynninen","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2013.09.024","article-title":"Preoperative 18F-FDG PET\/CT in the management of advanced epithelial ovarian cancer","volume":"131","author":"Fruscio","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1993.1268","article-title":"Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma","volume":"51","author":"Karlan","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.007_bib22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2214\/ajr.176.6.1761449","article-title":"Clinical value of positron emission tomography with FDG for recurrent ovarian cancer","volume":"176","author":"Nakamoto","year":"2001","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00261-007-9218-0","article-title":"PET-CT vs. CT alone in ovarian cancer recurrence","volume":"33","author":"Sebastian","year":"2008","journal-title":"Abdom Imag"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.007_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.007_bib28","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1007\/s00259-021-05450-9","volume":"48","author":"Delgado Bolton","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2018","key":"10.1016\/j.cpet.2023.12.007_bib29","first-page":"000091","article-title":"Utility of 18F-FDG-PET\/CT imaging in patients with recurrent gynecological malignancies prior to pelvic exenteration","volume":"ijgc","author":"Kim","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiol.2332031800","article-title":"Integrated FDG PET\/CT in patients with persistent ovarian cancer: correlation with histologic findings","volume":"233","author":"Sironi","year":"2004","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.007_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/RLU.0000000000000768","article-title":"Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET\/CT","volume":"40","author":"Schmidt","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.007_bib32","first-page":"CD012567","article-title":"Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian\/fallopian tube\/primary peritoneal cancer","volume":"10","author":"Roze","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2007.11.002","article-title":"Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography\/computed tomography--a prospective study","volume":"108","author":"Risum","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.007_bib34","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1007\/s00330-015-3729-9","article-title":"Volume-based quantitative FDG PET\/CT metrics and their\u00a0association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery","volume":"25","author":"Vargas","year":"2015","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib35","first-page":"61","article-title":"Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers","volume":"13","author":"Tsoi","year":"2020","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.cpet.2023.12.007_bib36","doi-asserted-by":"crossref","unstructured":"Boria F, Chiva L, Carbonell M, et al. 18F-fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG PET\/CT) predictive score for complete resection in primary cytoreductive surgery. Int J Gynecol Cancer. 2022:ijgc-2022-003883.","DOI":"10.1136\/ijgc-2022-003883"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib37","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1097\/RLU.0000000000004417","article-title":"Development and validation of 18F-FDG PET\/CT-Based models for predicting successful complete cytoreduction during primary cytoreductive surgery for advanced ovarian cancer","volume":"48","author":"Kim","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rcl.2004.09.006","article-title":"Monitoring response to treatment in patients utilizing PET","volume":"43","author":"Avril","year":"2005","journal-title":"Radiol Clin North Am"},{"issue":"30","key":"10.1016\/j.cpet.2023.12.007_bib39","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","article-title":"Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer","volume":"23","author":"Avril","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","article-title":"18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"140","author":"Vallius","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.007_bib41","first-page":"1211","article-title":"Early assessment of response to neoadjuvant chemotherapy with 18F-FDG-PET\/CT in patients with advanced-stage ovarian cancer","volume":"52","author":"Chung","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-018-3961-z","article-title":"18)F-FDG-PET\/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer","volume":"45","author":"Vallius","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.007_bib43","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00259-020-05092-3","article-title":"Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET\/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer","volume":"48","author":"Aide","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clon.2018.04.007","article-title":"Clinical value of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in response evaluation after primary treatment of advanced epithelial ovarian cancer","volume":"30","author":"Hynninen","year":"2018","journal-title":"Clin Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.cpet.2023.12.007_bib46","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"supplement 1","key":"10.1016\/j.cpet.2023.12.007_bib47","first-page":"63","article-title":"FDG PET early metabolic response to the PARP inhibitor olaparib (AZD2281) in BRCA-deficient or recurrent high-grade ovarian carcinoma and BRCA-deficient or triple-negative breast cancer","volume":"53","author":"Benard","year":"2012","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib48","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2023.12.007_bib49","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1200\/EDBK_280539","article-title":"Immune therapy opportunities in ovarian cancer","volume":"40","author":"Kandalaft","year":"2020","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.cpet.2023.12.007_bib51","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3348\/kjr.2020.1299","article-title":"Immunotherapy-related imaging findings in patients with gynecological malignancies: what radiologists need to know","volume":"22","author":"Russo","year":"2021","journal-title":"Korean J Radiol"},{"issue":"13","key":"10.1016\/j.cpet.2023.12.007_bib53","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2023.12.007_bib54","unstructured":"Yoshikawa K, Tanaka N, Hasebe M, et al. Comparison of C-11 methionine and FDG PET in detection and evaluation of ovarian tumor. J Nucl Med, 48 (supplement 2) 2007, 386P."},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2191-219X-3-27","article-title":"Optimization of [11C]methionine PET study: appropriate scan timing and effect of plasma amino acid concentrations on the SUV","volume":"3","author":"Isohashi","year":"2013","journal-title":"EJNMMI Res"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib56","first-page":"1051","article-title":"Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET","volume":"44","author":"Torizuka","year":"2003","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jcmm.14745","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in cancer","volume":"24","author":"An","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/BST20160387","article-title":"Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis","volume":"45","author":"Erdogan","year":"2017","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.007_bib60","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","article-title":"68)Ga-FAPI-PET\/CT in patients with various gynecological malignancies","volume":"48","author":"Dendl","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.007_bib61","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10967-022-08329-7","article-title":"Preliminary evaluation and in\u00a0vitro cytotoxicity studies of [131I]I-trastuzumab in HER2 expressing ovarian cancer cells","volume":"331","author":"Deng","year":"2022","journal-title":"J\u00a0Radioanal Nucl Chem"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/gyno.1997.4870","article-title":"Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies","volume":"67","author":"Juweid","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.007_bib63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12149-015-0980-8","article-title":"Assessment of 99mTc-MIBI SPECT(\/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study","volume":"29","author":"Kurata","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13550-014-0054-2","article-title":"Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model","volume":"4","author":"Lindenblatt","year":"2014","journal-title":"EJNMMI Res"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.007_bib65","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of (99m)Tc-labeled FAPI tracers for SPECT imaging and (188)Re therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40658-020-00290-2","article-title":"State of the art in total body PET","volume":"7","author":"Vandenberghe","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.007_bib67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/diagnostics12020426","article-title":"Advantages and applications of total-body PET scanning","volume":"12","author":"Katal","year":"2022","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib68","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2967\/jnumed.119.226498","article-title":"First human imaging studies with the EXPLORER total-body PET scanner","volume":"60","author":"Badawi","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.007_bib69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2967\/jnumed.119.231845","article-title":"PennPET explorer: human imaging on a whole-body imager","volume":"61","author":"Pantel","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.007_bib70","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00259-021-05282-7","article-title":"Clinical performance of long axial field of view PET\/CT: a head-to-head intra-individual comparison of the biograph vision quadra with the biograph vision PET\/CT","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.007_bib71","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.121.261972","article-title":"Performance characteristics of the biograph vision quadra PET\/CT system with a long axial field of view using the NEMA NU 2-2018 standard","volume":"63","author":"Prenosil","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.007_bib72","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3390\/cancers15092407","article-title":"Long axial field-of-view PET\/CT could answer unmet needs in gynecological cancers","volume":"15","author":"Triumbari","year":"2023","journal-title":"Cancers"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:11:12Z","timestamp":1761563472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859823001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1556859823001001"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.007","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/Computed Tomography Transformation of Oncology","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}